{"id":101056,"date":"2026-08-10T17:34:46","date_gmt":"2026-08-10T08:34:46","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4365-20260810-01_wp_financial_summary\/"},"modified":"2026-08-10T17:34:46","modified_gmt":"2026-08-10T08:34:46","slug":"4365-20260810-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/","title":{"rendered":"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary"},"content":{"rendered":"<p>Net sales of 11,135 million yen (YoY +6.1%), operating income of 2,270 million yen (YoY +12.1%), net income attributable to owners of parent of 2,004 million yen. Segments include Japan and Asia, and due to resource reallocation and demand recovery, results are solid.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4365","jir_company_name":"Matsumoto Abies Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4365-20260810-01.pdf","jir_short_summary":"Net sales of 11,135 million yen (YoY +6.1%), operating income of 2,270 million yen (YoY +12.1%), net income attributable to owners of parent of 2,004 million yen. Segments include Japan and Asia, and due to resource reallocation and demand recovery, results are solid.","jir_summary":"### Section Heading\nThis Financial Summary outlines the consolidated results and financial position for the first quarter of the fiscal year ending March 2027. Demand is recovering mainly in Japan and Asia, and while considering raw material and energy costs, sales and profits are above the previous year's first quarter. Segment results show notable contributions from Japan and Asia, with SG&A management and exchange rate effects being addressed.\n\n### Section 2 Heading\nThe financial position shows total assets increasing; liabilities have risen partly due to current liabilities, but equity and the equity ratio continue to improve. Cash flow notes are not prepared for this quarter, but the breakdown of depreciation and investment activities is disclosed. Future earnings guidance is based on published materials.","jir_financial_highlights":"Net sales: 11,135 (YoY +6.1%)\nOperating income: 2,270 (YoY +12.1%)\nNet income attributable to owners of parent: 2,004 (YoY +31.5%)","jir_category":"","jir_hashtags":"#MatsumotoAbiesPharmaceutical, #QuarterlyEarnings, #ManagementPerformance, #SegmentedSales","jir_key_figures":"Net sales: 11,135 million yen (YoY +6.1%)\nOperating income: 2,270 million yen (YoY +12.1%)\nNet income attributable to owners of parent: 2,004 million yen (YoY +31.5%)","jir_meta_title":"\u3010Matsumoto Abies Pharmaceutical\u3011FY2027 Q1 Financial Results Announcement | Net Sales 11,135 million yen, Operating Income 2,270 million yen","jir_meta_description":"Key points of Matsumoto Abies Pharmaceutical's FY2027 Q1 financial results. Net sales 11,135 million yen (up YoY 6.1%), operating income 2,270 million yen (up YoY 12.1%), net income 2,004 million yen. Summary by business segment and future outlook.","jir_og_title":"Matsumoto Abies Pharmaceutical | Revenue Up and Profit Expansion in Q1","jir_og_description":"Summary of Matsumoto Abies Pharmaceutical's FY2027 Q1 results. Net sales 11,135 million yen, operating income 2,270 million yen, net income 2,004 million yen. Segment trends and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":16710,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101056","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/\",\"name\":\"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-08-10T08:34:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/","name":"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-08-10T08:34:46+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4365\/ir\/4365-20260810-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Matsumoto Abies Pharmaceutical Co., Ltd. (4365) FY2027 March Quarter 1 Financial Summary"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"16710","title":"MATSUMOTO YUSHI SEIYAKU CO","ticker":"4365"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/101056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=101056"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/101056\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=101056"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=101056"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=101056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}